



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound selected from one of the following:



(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-
5-oxo-cyclopentaneheptanoic acid
[RSS]




(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-
5-oxo-cyclopentaneheptanoic acid
[RSR]


; or

or a salt, solvate, chemically protected form or prodrug thereof.

2. (Original) (*trans*-2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 90% by weight is selected from one of the following forms:



(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-
5-oxo-cyclopentaneheptanoic acid
[RSS]




(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-
5-oxo-cyclopentaneheptanoic acid
[RSR]


; or

or a salt, solvate, chemically protected form or prodrug thereof.

3. (Original) 2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 80% by weight is in one of the following forms:



(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-
5-oxo-cyclopentaneheptanoic acid
[RSS]



(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-
5-oxo-cyclopentaneheptanoic acid
[RSR]

; or

or a salt, solvate, chemically protected form or prodrug thereof.

4. (Currently Amended) A method of making a compound according to ~~any one of~~ claim 1 to 3.

5. (Currently Amended) A compound according to ~~any one of claim 1 to 3~~, or a pharmaceutically acceptable salt thereof, for use in a method of therapy.

6. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of claim 1 to 3~~, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

7. (Currently Amended) The use of a compound according to ~~any one of~~
~~claims~~claim 1 to 3, or a pharmaceutically acceptable salt thereof in the preparation of a
medicament for the treatment of a condition alleviated by agonism of an EP₂ receptor.

8. (Original) The use according to claim 7, wherein the condition alleviated by
agonism of an EP₂ receptor is selected from the group consisting of: glaucoma,
dysmenorrhoea and pre-term labour.

9. (Currently Amended) A method of treating a condition which can be alleviated by
agonism of an EP₂ receptor, which method comprises administering to a patient in need
of treatment an effective amount of a compound according to ~~any one of claims~~claim 1
~~to 3~~, or a pharmaceutically acceptable salt thereof.

10. (Original) The method according to claim 9, wherein the condition alleviated by
agonism of an EP₂ receptor is selected from the group consisting of: glaucoma,
dysmenorrhoea and pre-term labour.

11. (Original) The use of an EP₂ receptor agonist, or a pharmaceutically acceptable
salt thereof in the preparation of a medicament for the treatment of a condition
alleviated by the inhibition of:

- (i) human T-cell activation (proliferation);
- (ii) the release of IL-2;
- (iii) the release of TNF_α; or

(iv) the release of IFN γ .

12. (Original) The use of an EP₂ receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of psoriasis.

13. (Original) The use of an EP₂ receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of inflammatory lung diseases.

14. (Currently Amended) A use according to ~~any one of claims~~ claim 11 to 13, wherein the EP₂ receptor agonist is a compound of ~~any one of claims 1 to 3~~.

15. (Original) A method of treating a condition which can be alleviated by the inhibition of:

- (i) human T-cell activation (proliferation);
- (ii) the release of IL-2;
- (iii) the release of TNF α ; or
- (iv) the release of IFN γ ;

which method comprises administering to a patient in need of treatment an effective amount of an EP₂ receptor agonist, or a pharmaceutically acceptable salt thereof.

16. (Original) A method of treating a psoriasis, which method comprises administering to a patient in need of treatment an effective amount of an EP₂ receptor agonist, or a pharmaceutically acceptable salt thereof.

17. (Original) A method of treating an inflammatory lung disease, which method comprises administering to a patient in need of treatment an effective amount of an EP₂ receptor agonist, or a pharmaceutically acceptable salt thereof.

18. (Currently Amended) A method according to ~~any one of claims~~ claim 15 to 17, wherein the EP₂ receptor agonist is a compound of ~~any one of claims 1 to 3~~.